Predictors of response to ovulation induction using letrozole in women with polycystic ovary syndrome.
Letrozole
Ovulation
Polycystic ovary syndrome
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
25 Apr 2023
25 Apr 2023
Historique:
received:
31
12
2022
accepted:
07
04
2023
medline:
27
4
2023
pubmed:
26
4
2023
entrez:
25
4
2023
Statut:
epublish
Résumé
This study aimed to evaluate the predictive value of the initial screening characteristics of women with anovulatory polycystic ovary syndrome (PCOS) who did or did not respond to 2.5 mg letrozole (LET). The clinical and laboratory characteristics of women with PCOS who underwent LET treatment were evaluated. Women with PCOS were stratified according to their responses to LET (2.5 mg). The potential predictors of their responses to LET were estimated using logistic regression analysis. Our retrospective study included 214 eligible patients with a response to 2.5 mg LET (n = 131) or no response to 2.5 mg LET (n = 83). PCOS patients who responded to 2.5 mg LET showed better outcomes than those who did not (2.5 mg LET) for pregnancy rate, live birth rate, pregnancy rate per patient, and live birth rate per patient. Logistic regression analyses showed that late menarche (odds ratio [OR], 1.79 [95% confidence intervals (CI), 1.22-2.64], P = 0.003), and increased anti-müllerian hormone (AMH) (OR, 1.12 [95% CI, 1.02-1.23], P = 0.02), baseline luteinizing hormone (LH)/ follicle stimulating hormone (FSH) (OR, 3.73 [95% CI, 2.12-6.64], P < 0.001), and free androgen index (FAI) (OR, 1.37 [95% CI, 1.16-1.64], P < 0.001) were associated with a higher possibility of no response to 2.5 mg LET. PCOS patients with an increased LH/FSH ratio, AMH, FAI, and late menarche may need an increased dosage of LET for a treatment response, which could be helpful in designing a personalized treatment strategy.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to evaluate the predictive value of the initial screening characteristics of women with anovulatory polycystic ovary syndrome (PCOS) who did or did not respond to 2.5 mg letrozole (LET).
METHODS
METHODS
The clinical and laboratory characteristics of women with PCOS who underwent LET treatment were evaluated. Women with PCOS were stratified according to their responses to LET (2.5 mg). The potential predictors of their responses to LET were estimated using logistic regression analysis.
RESULTS
RESULTS
Our retrospective study included 214 eligible patients with a response to 2.5 mg LET (n = 131) or no response to 2.5 mg LET (n = 83). PCOS patients who responded to 2.5 mg LET showed better outcomes than those who did not (2.5 mg LET) for pregnancy rate, live birth rate, pregnancy rate per patient, and live birth rate per patient. Logistic regression analyses showed that late menarche (odds ratio [OR], 1.79 [95% confidence intervals (CI), 1.22-2.64], P = 0.003), and increased anti-müllerian hormone (AMH) (OR, 1.12 [95% CI, 1.02-1.23], P = 0.02), baseline luteinizing hormone (LH)/ follicle stimulating hormone (FSH) (OR, 3.73 [95% CI, 2.12-6.64], P < 0.001), and free androgen index (FAI) (OR, 1.37 [95% CI, 1.16-1.64], P < 0.001) were associated with a higher possibility of no response to 2.5 mg LET.
CONCLUSIONS
CONCLUSIONS
PCOS patients with an increased LH/FSH ratio, AMH, FAI, and late menarche may need an increased dosage of LET for a treatment response, which could be helpful in designing a personalized treatment strategy.
Identifiants
pubmed: 37098539
doi: 10.1186/s12902-023-01336-z
pii: 10.1186/s12902-023-01336-z
pmc: PMC10127327
doi:
Substances chimiques
Letrozole
7LKK855W8I
Fertility Agents, Female
0
Follicle Stimulating Hormone
9002-68-0
Luteinizing Hormone
9002-67-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90Subventions
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-B-081
Informations de copyright
© 2023. The Author(s).
Références
Endocr Rev. 2015 Oct;36(5):487-525
pubmed: 26426951
Hum Reprod. 1995 Sep;10(9):2377-81
pubmed: 8530669
Gynecol Endocrinol. 2019 Jan;35(1):86-89
pubmed: 30044165
Sci Rep. 2021 Oct 14;11(1):20490
pubmed: 34650180
Reprod Biomed Online. 2023 Jan;46(1):156-163
pubmed: 36411204
Nat Rev Dis Primers. 2016 Aug 11;2:16057
pubmed: 27510637
J Clin Endocrinol Metab. 2013 Oct;98(10):4170-5
pubmed: 23979947
Hum Reprod. 2017 Aug 1;32(8):1631-1638
pubmed: 28854590
Reprod Biomed Online. 2018 Aug;37(2):163-171
pubmed: 29778554
Reprod Biol Endocrinol. 2013 Dec 17;11:115
pubmed: 24341292
Fertil Steril. 2002 Jan;77(1):91-7
pubmed: 11779596
J Hum Reprod Sci. 2021 Jul-Sep;14(3):326
pubmed: 34759627
J Int Med Res. 2021 May;49(5):3000605211018600
pubmed: 34038202
N Engl J Med. 2014 Jul 10;371(2):119-29
pubmed: 25006718
J Clin Endocrinol Metab. 2009 Sep;94(9):3458-66
pubmed: 19509098
Trends Endocrinol Metab. 2008 Nov;19(9):340-7
pubmed: 18805020
J Matern Fetal Neonatal Med. 2018 Jan;31(1):32-38
pubmed: 27978775
J Endocrinol Invest. 2016 Jul;39(7):799-803
pubmed: 26797707
Endocrine. 2010 Oct;38(2):243-53
pubmed: 21046485
J Assist Reprod Genet. 2021 Jul;38(7):1827-1833
pubmed: 33934267
Hum Reprod Update. 2008 Jul-Aug;14(4):367-78
pubmed: 18499708
J Clin Invest. 1976 May;57(5):1320-9
pubmed: 770505
J Reprod Med. 2013 May-Jun;58(5-6):219-23
pubmed: 23763006
J Clin Endocrinol Metab. 2016 Sep;101(9):3288-96
pubmed: 27228369
Hum Reprod. 2011 Jan;26(1):245-52
pubmed: 21071489
Fertil Steril. 2006 Feb;85(2):277-84
pubmed: 16595197
Hum Reprod. 2008 Mar;23(3):462-77
pubmed: 18308833
Hum Reprod. 1995 Oct;10(10):2545-9
pubmed: 8567767
N Engl J Med. 2007 Feb 8;356(6):551-66
pubmed: 17287476
Indian J Endocrinol Metab. 2019 Mar-Apr;23(2):257-262
pubmed: 31161114
Heliyon. 2023 Jan 18;9(1):e13024
pubmed: 36711322
Hum Reprod. 2018 Sep 1;33(9):1602-1618
pubmed: 30052961
Biol Reprod. 1985 Sep;33(2):363-9
pubmed: 2994766
Fertil Steril. 2016 Dec;106(7):1742-1750
pubmed: 27666564
Fertil Steril. 2018 Aug;110(3):364-379
pubmed: 30033227
Reprod Biol Endocrinol. 2020 Mar 10;18(1):20
pubmed: 32156287